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Proanthocyanidins (PACs) are polymers of flavan-3-ols abundant in many vegetable 
foods and beverages widely consumed in the human diet. There is increasing evidence 
supporting the beneficial impact of dietary PACs in the prevention and nutritional 
management of non-communicable chronic diseases. It is considered that PACs with 
a degree of polymerization >3 remain unabsorbed in the gastrointestinal (GI) tract and 
accumulate in the colonic lumen. Accordingly, the GI tract may be considered as a key 
organ for the healthy-promoting effects of dietary PACs. PACs form non-specific com-
plexes with salivary proteins in mouth, originating the sensation of astringency, and with 
dietary proteins, pancreatic enzymes, and nutrient transporters in the intestinal lumen, 
decreasing the digestion and absorption of carbohydrates, proteins, and lipids. They 
also exert antimicrobial activities, interfering with cariogenic or ulcerogenic pathogens 
in the mouth (Streptococcus mutans) and stomach (Helicobacter pylori), respectively. 
Through their antioxidant and antiinflammatory properties, PACs decrease inflammatory 
processes in animal model of gastric and colonic inflammation. Interestingly, they exert 
prebiotic activities, stimulating the growth of Lactobacillus spp. and Bifidobacterium 
spp. as well as some butyrate-producing bacteria in the colon. Finally, PACs are also 
metabolized by the gut microbiota, producing metabolites, mainly aromatic acids and 
valerolactones, which accumulate in the colon and/or are absorbed into the blood-
stream. Accordingly, these compounds could display biological activities on the colonic 
epithelium or in extra-intestinal tissues and, therefore, contribute to part of the beneficial 
effects of dietary PACs.
Keywords: proanthocyanidins, gastrointestinal tract, Helicobacter pylori, intestinal microbiota, digestive enzymes
Abbreviations: PACs, proanthocyanidins; DP, degree of polymerization; GI, gastrointestinal; Helicobater pylori, H. pylori; VacA, 
vacuolating cytotoxin A; HMW, high molecular weight; LMW, low molecular weight; NSAIDs, non-steroidal antiinflammatory 
drugs; NOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase; SH, sulfhydryl compounds; EGF, epidermal growth 
factor; PCNA, proliferating cell nuclear antigen; NO, nitric oxide; GLP-1, glucagon-like peptide-1; SGLT1, sodium–glucose 
cotransporter 1; GLUT, glucose transporter; TG, triglycerides; CS, cholesterol; FFAs, free fatty acids; IBAT, ileal bile acid 
transporter; AUC, area under the curve; NPC1L1, Niemann–Pick C1-like protein 1; LPS, lipopolysaccharide; IM, intestinal 
microbiota; SCFAs, short chain fatty acids; IBD, inflammatory bowel diseases; OR, odds ratio.
FiGuRe 2 | Type-A and type-B proanthocyanidins.
FiGuRe 1 | Chemical structure of flavanol units conforming proanthocyanidins.
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iNTRODuCTiON
Polyphenols are secondary metabolites synthesized by plants, 
which are implicated in their protection against microbial patho-
gens, predators, ultraviolet radiation, and adverse conditions of 
nutrition and growth (1, 2). They are classified as non-flavonoids 
and flavonoids, being these latter the major group of phyto-
chemicals present in the human diet. The flavonoid chemical 
structure is characterized by two aromatic rings connected by 
a three-carbon bridge (C6–C3–C6) (3, 4). The main subclasses 
of flavonoids are flavones, flavonols, flavan-3-ols, isoflavones, 
flavanones, and anthocyanidins (3). The flavan-3-ols (also called 
flavanols) are the most complex as they include not only simple 
monomers but also oligomeric and polymeric proanthocyani-
dins (PACs), known as condensed tannins (3). Accordingly, PAC 
size is variable and depends on their degree of polymerization 
(DP), i.e., the amount of monomers of flavan-3-ols incorporated 
in the molecule. The DP commonly varies between 3 and 11 but 
can even reach up 50 units or more. For example, the average DP 
of black gooseberry (Ribes nigrum) PACs is about 48, whereas in 
wine and beer PACs, it is only 7 and 2, respectively (3, 5). PACs are 
abundant in many foods and beverages like seeds, barks, fruits, 
red wine, cider, tea, cocoa, and beer, where they contribute to 
their bitter taste and astringency (4, 5). Depending on the units 
of flavanols involved in their structure, PACs are subdivided in 
different classes. The most abundant consist exclusively of (epi)
catechin units and are called procyanidins (PCs), while the 
less common containing (epi)afzelechin or (epi)gallocatechin 
subunits are named propelargonidins and prodelphinidins, 
respectively (3, 4, 6, 7) (Figure 1). PACs may also be classified as 
type-A or -B according to the interflavanol linkage; type-B PACs 
are found in a greater abundance and have only one C–C interfla-
van bond, while type-A are less common and are characterized 
by an additional ether linkage (7) (Figure 2). Type-B PACs are 
present in fruits (apples, grapes, pears), legumes, cereals (barley, 
sorghum), cocoa, and their derived foodstuffs (wine, cider, beer, 
etc.), while A-type are found in cranberry, cinnamon, apricots, 
and avocado, among others; some foodstuffs have mixed type-A 
and -B PACs (7–10).
The beneficial impact of dietary PACs on the risk of cancer 
(5,  11, 12), cardiovascular diseases (5, 13, 14), and diabetes 
(12, 15, 16) is supported by a large number of in vitro, animal, 
clinical, and epidemiological studies. These health-promoting 
effects suggest that PACs may be absorbed by the intestinal 
FiGuRe 3 | interactions between dietary proanthocyanidins and the gastrointestinal tract.
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mucosa. However, evidence indicates that only monomers, 
dimers and, eventually, trimers of flavan-3-ols are absorbable, 
while oligomers and polymers of higher DP remain unabsorbed 
and accumulate in the gut lumen. Non-absorbed PACs reach the 
colon where they are metabolized by the microbiota, producing 
low molecular weight (LMW) compounds (4, 7, 17–19) that 
may be absorbed into the circulation. Therefore, the beneficial 
effect of PACs on human health may be attributed not only to 
the circulating monomers or dimers of flavanols but also to the 
microbiota-derived PAC metabolites present in the bloodstream 
(7). Additionally, PACs and/or their bacterial metabolites may 
exert health benefits directly in the gastrointestinal (GI) tract 
through their antioxidant, antiinflammatory, antibacterial, and 
antiproliferative properties (12).
The present review describes how dietary PACs impact the 
main physiological processes occurring in the GI tract and exerts 
protective properties in pathological conditions (Figure  3). 
More particularly, it addresses the fate of PACs in the different 
compartments of the GI tract, describing their absorption and 
metabolism, and their ability to interfere with the processes 
of digestion and absorption of macronutrients in the intestine 
and to modulate digestive hormone secretion, hydroelectrolytic 
epithelial transport, and GI motility. In parallel, this review 
also describes the protective effects displayed by dietary PACs 
including the attenuation of enteropathogen deleterious activi-
ties and gastric and colonic inflammatory processes. Finally, it 
addresses their prebiotic effect in the colon, their transforma-
tion by the microbiota, and their role in decreasing the risk of 
colorectal cancer.
PACs iN THe MOuTH
Dietary PACs have been shown to bind and precipitate salivary 
proteins containing high-proline contents, a phenomenon that 
constitutes the physiologic base of astringency perception after 
consuming PAC-containing foodstuffs (20). Catechins were 
detected in saliva for up to 60  min after using a mouth rins-
ing product containing green tea extract (5  mg/ml) (21); the 
persistence of these compounds in saliva could favor their anti-
microbial activity against some oral bacteria. More particularly, 
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cranberry PACs have been shown to inhibit the adhesion of the 
cariogenic bacteria Streptococcus mutans to oral epithelial cells, 
thus preventing the formation of pathogen biofilm in the tooth 
surface (22, 23). On the other hand, PACs containing galloyl 
moieties have been recently proposed as a useful tool in restora-
tive and reparative dentistry, due to their ability to act as dentin 
biomodifiers (24).
PACs iN THe STOMACH
Protective effect against 
Helicobacter pylori (H. pylori)
Helicobacter pylori is a helix-shaped, microaerophilic, Gram-
negative, flagellated bacterium that specifically colonizes the 
human gastric mucosa. It is considered as the most widespread 
chronic bacterial pathogen in the world, infecting more than 50% 
of the human population. Although over 80% of the infected 
individuals remain asymptomatic, H. pylori is implicated as an 
etiologic factor in the development of a variety of GI diseases 
including gastroduodenal ulcers and gastric adenocarcinoma 
and lymphoma. Accordingly, this pathogen is classified as a 
class I carcinogen (25–27). H. pylori expresses several virulence 
factors involved in the initial colonization of the gastric mucosa 
by the bacteria and in its persistence in the stomach. These 
factors include (1) adhesins, bacterial surface proteins allowing 
the adherence of this agent to the gastric epithelial cells, (2) an 
urease activity that releases ammonia from urea hydrolysis, 
allowing proton neutralization and the survival of the bacteria 
in the acidic gastric environment, (3) the vacuolating cytotoxin 
A (VacA) that alters the mitochondrial function of the epithelial 
cells and promotes their vacuolization and subsequent apoptosis, 
in addition to influencing host tolerance by suppressing T cell 
activation, and (4) the cag pathogenicity island encoding a type 
IV secretion system, which is involved in the development of 
inflammatory processes in the mucosa (27–29).
The administration of PACs-rich beverages decreases H. pylori 
colonization in humans. A prospective, randomized, double-
blind, placebo-controlled trial conducted in China in 189 adult 
patients colonized by H. pylori provided some clinical support 
for the anti-H. pylori effect of cranberry juice that contains large 
amounts of A-type PACs (30, 31). The participants were assigned 
to receive 250 ml of cranberry juice or placebo twice daily for 
90 days. H. pylori colonization was determined by 13C-urea breath 
test after 35 and 90  days of treatment. The eradication of the 
pathogen was reported in 14.4% of the treated subjects compared 
with 5.3% in the placebo group. Similar results were reported 
in a clinical trial carried out in 295 Chilean children colonized 
by H. pylori. The intake of 200  ml cranberry juice per day for 
3  weeks induced the eradication of the pathogen in 16.9% of 
the treated children vs 1.5% in the placebo group. Interestingly, 
the coadministration of cranberry juice with the probiotic, 
L. johnsonii NCC533, eradicated the bacteria in 22.9% of the 
children (32). The mechanisms associated with the anti-H. pylori 
activity of cranberry PACs include their ability to inhibit urease 
activity and prevent bacterial adhesion as well as VacA-induced 
mucosal damage (Table 1). High molecular mass, non-dialyzable 
constituents of cranberry juice, subsequently characterized as 
PACs, have been shown to inhibit the adhesion of clinically 
isolated H. pylori strains to AGS gastric cell line. As no cross-
resistance was detected between the non-dialyzable material 
and metronidazole, it was suggested that cranberry preparations 
could improve H.  pylori eradication in untreated patients as 
well as in those under pharmacological treatment (33). In vitro 
studies consistently indicate that high molecular weight (HMW) 
components from cranberry inhibit the sialyllactose-specific (S 
fimbriae) adhesion of H. pylori to immobilized human mucus, 
erythrocytes, and cultured gastric epithelial cells (34, 35). This 
anti-adhesion effect was not restricted to cranberry PACs and 
was also reported with dietary PACs from different sources. 
Pycnogenol®, a standardized concentrate elaborated from French 
maritime pine bark and which contains PAC from dimers (mainly 
type B) to polymers (up to 12 monomeric units of flavanol) (36, 
37), inhibited concentration-dependently the adhesion of clini-
cal strains of H. pylori to AGS cells (38). A  root  extract from 
Pelargonium sidoides, rich in polymeric PACs (39), has also been 
shown to prevent H. pylori adhesion to intact human stomach 
tissue (40–42).
Proanthocyanidins can also interfere with H. pylori by inhibit-
ing its urease activity and/or by inactivating VacA. For example, 
a methanol extract of Eucalyptus grandis (Myrtaceae) bark was 
shown to inhibit the urease of clinical strains of H. pylori in a 
concentration-dependent manner. This effect was attributed to 
the tannins and triterpene saponins present in the extract (43). 
Some studies suggest that PAC DP is a determining factor for 
urease inhibition or their protective effects on VacA-induced 
mucosal damage. LMW PAC fraction (mean DP of 3) derived 
from apple peel exhibited an urease inhibition fourfold lower than 
the high HMW fraction (mean DP of 9.5) (44). More recently, 
an aqueous extract of Peumus boldus Mol. (Monimiaceae) rich 
in catechin-derived PCs B3 and C2 was also shown to inhibit 
H. pylori urease (45). The separation of the extract components 
according to their molecular weight revealed that the higher 
the DP, the greater the urease inhibition. Interestingly, the 
catechin-derived PCs (B3 and C2) were more effective than the 
epicatechin-derived PCs B2 and C1 in inhibiting the urease, 
suggesting that not only DP is important but also the chemical 
nature of the monomer bound to C-4 in the PC structure (45). 
A structure–activity relationship between PAC DP and their 
ability to inactivate VacA cytotoxin has also been established 
with hops extracts (46). Accordingly, the administration of red 
wine or green tea mixture to H. pylori-infected mice significantly 
prevented the development of gastritis, limiting the localization 
of the pathogen and VacA toxin on the surface of the gastric 
epithelium (47).
On the other hand, exciting advances in the knowledge of 
the interactions between PCs and target molecules are emerg-
ing from molecular docking studies. Such studies, for example, 
revealed that B-type PCs (catechin dimers) inhibit urease because, 
according to their docking scores (−6.9  kcal/mol), they fit the 
binding pocket of the bacterial enzyme, being these interactions 
energetically favorable (48). Then, molecular docking could 
TABle 1 | Anti-Helicobacter pylori (H. pylori) effects of proanthocyanidins.
effects extract-compound Model Reference
Decrease of H. pylori 
colonization
250 ml Vaccinium macrocarpon juice, twice a day, for 35 and 90 days 189 human adults (30)
Decrease of H. pylori 
colonization
200 ml V. macrocarpon juice per day for 3 weeks 295 children (32)
Inhibition of the 
adhesion of H. pylori 
strains to epithelia
High molecular mass non-dialyzable constituents of V. macrocarpon 
juice
AGS cells (33)
High molecular mass constituents from V. macrocarpon juice Human gastric mucus
HT-29 cells
(34, 35)
Pycnogenol®, a standardized PACs (B-type, C4–C8 bonds) extract from 
the French maritime pine bark
AGS cells (38)
Pelargonium sidoides root extract containing mainly polymeric PACs In situ anti-adhesion assay to intact human 
stomach tissue
(40–42)
Inhibition of urease 
activity
Eucalyptus grandis (Myrtaceae) stem bark extract Urease from three clinical isolates H. pylori strains (43)
An Malus domestica peel polyphenol extract (APPE), containing 
epicatechin-derived procyanidins (PCs) B1, B2, and C1
APPE-derived high molecular weight (HMW) extract
APPE-derived low molecular weight (LMW) extract
H. pylori (ATCC 43504) and Jack bean ureases (44)
Peumus boldus aqueous extract (BAE), containing catechin-derived 
PCs B3 and C2
Subfraction of BAE according to the degree of polymerization content
H. pylori (ATCC 43504) and Jack bean ureases (45)
B-type PCs (catechin dimers) Molecular docking analysis of urease inhibition (48)
Vacuolating cytotoxin 
A (VacA) inhibition
Humulus lupulus bract extract (HBT) containing HMW polymerized 
catechins HBT-derived HMW extract
HBT-derived LMW extract
Mouse model of experimental VacA infection (46)
Red wine and green tea mixture Mouse model of experimental VacA and H. pylori 
infection
(47)
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contribute to elucidate the interactions between PCs and other 
cellular or bacterial targets of interest for the protection of the 
gastric mucosa against H. pylori.
Protective effect against Gastric 
inflammation
The gastroprotective properties of PAC extracts have been 
widely studied using different animal models of gastric inflam-
mation induced by ethanol, non-steroidal antiinflammatory 
drugs (NSAIDs), pylorus ligature, or restrain stress (Table  2). 
Synthetic PAC oligomers, more particularly those bigger than 
tetramers, protected the gastric mucosa against ethanol-induced 
damage, due to their ability to scavenge free radicals and, there-
fore, prevented the appearance of oxidative damage (49). Such 
effect could also be due to the protein-binding ability of the 
oligomers, which would allow them to form a protective layer 
coating the gastric mucosa. In another study, the administration 
of a single oral dose of Hawthorn berries extract (a mixture of 
Crataegus monogyna and C. oxyacantha containing 0.44% PACs) 
attenuated the intensity of ethanol-induced gastric lesions in 
rats, an effect similar to that observed with the administration of 
ranitidine (50). Considering the low proportion of PACs in this 
extract, it is improbable that these molecules were responsible 
for this protective effect; however, it is important to mention that 
Hawthorn berries contain oligomeric PACs and more B-type 
than A-type (51).
Proanthocyanidins were also protective in gastric damage 
induced by NSAIDs. Although NSAIDs are widely used for 
their antipyretic, analgesic, and antiinflammatory properties, 
their administration is frequently associated with adverse 
effects mainly affecting the GI mucosa (52, 53). NSAIDs and 
proton pump inhibitors (like omeprazole and lansoprazole) are 
frequently coprescribed to minimize NSAID-related adverse 
effects and the enteropathy induced by such combination, though 
common, is often clinically silent. Thus, the lesions induced by 
these drugs in the GI tract could be of considerable clinical 
importance. Accordingly, bioactive compounds, like PACs, arise 
as an alternative approach for the management of the adverse 
effects associated with NSAID therapies (53). The oral intake of 
PAC extracts from Guazuma ulmifolia (Sterculiaceae) or grape 
seed for 2–6 days before diclofenac or indomethacin administra-
tion in rats, prevented in a dose-dependent manner the develop-
ment of gastric mucosal damage and attenuated intestinal injury 
(54–56). These extracts decreased the area of ulceration induced 
by indomethacin in the stomach by decreasing lipid peroxida-
tion in the mucosa and by increasing the superoxide dismutase 
and glutathione peroxidase activities as well as the glutathione 
levels (54). The G. ulmifolia extract was also shown to prevent 
TABle 2 | Gastroprotective effects of proanthocyanidins.
extract-compound Model of gastric mucosal 
lesions
effects Reference
Synthetic proanthocyanidin oligomers
Single dose (200 mg/kg), p.o.
(HCl)/ethanol ↓ gastric lesion (49)
Gravinol S extract 0.002, 0.02, 0.2, and 1% in drinking 
water for 2 weeks
Water-immersion restraint ↓ gastric lesion
↓ MPO activity
↑ SOD activity
↓ gastrin and somatostatin levels
↑ PGE2 levels
(64)
Viburnum opulus extract 25, 50, or 75 mg/kg/day, p.o.
For 3 days
Water-immersion restraint ↓ gastric lesion
↑ NO expression
↑ SOD, CAT, and GSPHpx activities
(65)
Guazuma ulmifolia extract 500, 250, and 125 mg/kg/
day, p.o.
For 2 days
NSAID ↓ gastric lesion
↓ neutrophil infiltration
↓ lipid peroxidation
↑ SOD and GSHpx activities
No effect on PGE2 levels
(54)
Hippophaë rhamnoides L. extract 50, 100, and  
150 mg/kg/day, p.o.
For 7 or 14 days after acetic acid
Acetic acid Acceleration of mucosa repair
↑ plasmatic EGF
↑ EGFR and PCNA expressions in the  
gastric ulcer tissues
(63)
Hancornia speciosa extract
Single dose (250, 500, or 1,000 mg/kg), p.o.
(HCl)/ethanol NSAID ↓ gastric lesion (57)
H. speciosa extract
Single dose (500 mg/kg), p.o.
Hypothermic restraint ↓ gastric lesion (57)
Pylorus ligation ↓ gastric lesion
↑ pH, without changing the gastric volume
(57)
H. speciosa extract
500 mg/kg/day, p.o.
For 7 or 14 days after acetic acid
Acetic acid Acceleration of mucosa repair (57)
Cecropia glazioui Sneth extract butanolic fraction
Single dose (0.05–0.5 g/kg), p.o.
(HCl)/ethanol
NSAID
Hypothermic restraint
↓ gastric lesion (60)
C. glazioui Sneth extract butanolic fraction
Single dose (0.5–2.0 g/kg), i.d.
Pylorus ligation ↓ gastric lesion
↓ acid secretion, volume, and acidity
(60)
Crataegus monogyna and Cratageus oxycantha extract
Single dose (50–200 mg/kg), p.o.
(HCl)/ethanol ↓ gastric lesion (50)
Curatella americana L. hydroalcoholic extract
Single dose (100, 250, 500, or 1,000 mg/kg), p.o.
NSAID ↓ gastric lesion (58)
(HCl)/ethanol ↓ gastric lesion
↓ gastrin hormone levels
↑ somatostatin hormone levels
↑ PGE2 levels
↑ mucus production
(58)
C. americana L. hydroalcoholic extract
Single dose (500 mg/kg), p.o.
Hypothermic restraint ↓ gastric lesion (58)
Pylorus ligation ↓ gastric lesion
↑ gastric pH
(58)
C. americana L. hydroalcoholic extract
500 mg/kg/day, p.o.
For 14 days after acetic acid
Acetic acid Acceleration of mucosa repair (58)
Byrsonima intermedia extract
Single dose (250, 500, or 1,000 mg/kg), p.o.
(HCl)/ethanol, NSAID ↓ gastric lesion (61)
(Continued )
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extract-compound Model of gastric mucosal 
lesions
effects Reference
B. intermedia extract
Single dose (500 mg/kg), p.o.
Pylorus ligation ↓ gastric lesion
↑ gastric volume, without  
changing the pH
(61)
B. intermedia extract
500 mg/kg/day, p.o.
For 7 or 14 days after acetic acid
Acetic acid Acceleration of mucosa repair (61)
Vitis vinifera seed proanthocyanidin extracts
100 and 300 mg/kg/day, p.o.
For 6 days
NSAID ↓ gastric lesion
↑ glutathione levels
No effect in PGE2 levels
(55)
CAT, catalase; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; GSPHpx, gluthatione peroxidase; i.d. intraduodenally; MPO, myeloperoxidase; NO, nitric 
oxide; NSAID, non-steroidal antiinflammatory drug; PCNA, proliferating cell nuclear antigen; p.o. orally; SOD, superoxide dismutase; PGE2, prostaglandin E2.
TABle 2 | Continued
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neutrophil infiltration (reflected by a lower myeloperoxidase 
activity) in the mucosa (54).
Proanthocyanidin extracts from medicinal plants includ-
ing Mangaba (Hancornia speciosa) (containing LMW PACs), 
Curatella americana L. (Dilleneaceae) (containing oligomeric 
and polymeric PACs), Cecropia glazioui Sneth (Cecropiaceae) 
(that contains 22% of PACs B2, B3, B5, and C1), and Byrsonima 
intermedia (containing oligomeric PACs, phenolic acids, and 
catechin derivatives and flavonoids) have also been evaluated 
(57–61). The oral administration of a single dose of each extract 
decreased the gastric lesions induced by indomethacin or piroxi-
cam, hypothermic restraint stress, ethanol, or pylorus ligature, in 
the same extent that cimetidine, ranitidine, or lansoprazole (57, 
58, 60, 61). Interestingly, the extraction step seems to be critical 
to determine the antiulcer effects of the bioactive compounds; no 
significant protective effects were observed when plant infusions 
were used (57, 58).
Another mechanism by which PACs may protect the gastric 
mucosa is through the modulation of HCl secretion. Plant 
extracts decreased the secretion of HCl by gastric parietal cells 
when administered intraduodenally to pylorus-ligated mice (57, 
58, 60, 61). The C. glazioui extract reversed the histamine or 
bethanechol-induced acid secretion to basal values, indicating it 
inhibits the proton pump. This antisecretory effect was compara-
ble to that observed with the histamine H2 receptor-antagonist, 
ranitidine (60). It is possible that this effect relies on the type-B2 
PACs since these molecules displayed the highest inhibitory 
activity against the gastric H+, K+-ATPase in  vitro, compared 
with the other type of PACs isolated from C. glazioui (like B3, 
B5, and C1) (60).
The PAC antiulcer properties are also related to their ability to 
stimulate mucus synthesis and secretion (62), and to their mucosal 
repair activity. Indeed, they were shown to accelerate the healing 
of gastric ulcer induced by acetic acid administration (57, 58, 61). 
It is probable that nitric oxide synthase (NOS), sulfhydryl com-
pounds (SH), and TRPV-vanilloid receptors were involved in this 
phenomenon, as pretreatment with NOS inhibitor (L-NAME), 
SH-blocker (NEM), or TRPV receptor inhibitor (ruthenium red) 
blocked the PACs protection against ethanol-induced gastric 
damage (57, 58, 61). The increased expression of key molecules 
implicated in the restitution of the gastric epithelium during 
chronic gastroduodenal ulcers arises as another mechanism of 
protection exerted by PACs. For example, a sea buckthorn extract 
containing 96.5% PACs was shown to decrease the ulcer index in 
acetic acid-induced gastric lesions, in association with increased 
plasma concentrations of epidermal growth factor (EGF) and 
higher expression of EGF receptor and proliferating cell nuclear 
antigen in the gastric mucosa (63). These molecules are consid-
ered as crucial for the ulcer healing process and are implicated 
in epithelial restitution and gland reconstruction. The effect of 
PACs on trefoil peptides, also involved in the epithelial restitution 
process, has not been studied.
On the other hand, PACs could also exert their protective 
effects through endocrine and neural mechanisms. A C. ameri-
cana extract, for example, exhibited ulcer healing properties by 
increasing the mucosal levels of prostaglandin E2 and somato-
statin and decreasing those of gastrin (58). Gravinol S contain-
ing 89.3% PAC (25.2% dimers–pentamers, 74.8% oligomers) 
from grape seeds, when administered ad  libitum for 2  weeks, 
prevented gastric mucosal damage induced by water immersion 
restraint stress in rats. The authors proposed that PACs inhibit 
gastrin secretion by G cells and subsequently that of histamine 
and somatostatin, in addition to increase prostaglandin levels 
and superoxide dismutase activity in the gastric mucosa (64). 
Using the same animal model, a single dose of Viburnum opulus 
(Caprifoliaceae) PAC extract attenuated the gastroduodenal 
lesions. This effect was abrogated by capsaicin pretreatment, 
suggesting the implication of the nervous system. Moreover, 
the administration of this extract was also associated with the 
stimulation of the nitric oxide system, the increased resistance 
of the mucus layer, and the stimulation of mucosal superoxide 
dismutase and catalase activities (65).
effect on Gi Hormone Secretion 
and Gastric emptying
A few studies have evaluated the impact of PAC intake on the 
release of digestive hormones, some of them in relation to GI 
motility. González-Abuín et al. showed that rats fed a cafeteria 
diet exhibited a lower density of enteroendocrine cells in the 
intestinal epithelium and plasma concentrations of active 
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glucagon-like peptide-1 (GLP-1), and that these alterations were 
prevented with a grape seed PC extract (66). Since GLP-1 is an 
incretin hormone participating in the regulation of food intake 
and insulin secretion, it is possible that dietary PACs are ben-
eficial for the control of energetic metabolism in humans. There 
is no doubt that it is a promising field of research. Serrano et al. 
showed that the administration of a grape seed proanthocyanidin 
extract (423 mg phenolics/kg body weight) to rats increased the 
portal concentrations of active GLP-1 and ghrelin and decreased 
those of cholecystokinin. These findings were accompanied by 
a delayed gastric emptying and lower food intake in the treated 
animals (67). In another study, Ko et al. evaluated the effect of 
a whole grape juice (with skin and seeds) in rats treated with 
cisplatin, a chemotherapeutic drug known to provoke acute GI 
disorders. Cisplatin treatment decreased significantly the rate of 
gastric emptying compared with the control group, and pretreat-
ment with grape juice (10  ml/kg body weight) prevented this 
disturbance (68).
Antiemetic Properties
Miller et  al. evaluated the effect of an extract of Croton pala-
nostigma (100 mg/g of PACs) in the treatment of emesis induced 
by the administration of morphine-6-glucuronide in adult fer-
rets. The extract reduced by 77% the morphine-induced vomiting 
and retching, suggesting that it could suppress the activation 
of sensory afferent nerve implicated in the emetic reflex (69). 
According to these observations, Li et al. reported that a grape 
seed proanthocyanidin extract inhibits in a non-competitive 
manner the 5-hydroxytryptamine-3 receptors involved in the 
initiation and coordination of the vomiting reflex, in NCB-20 
neuroblastoma cells (70). Taking together, these results suggest 
that PAC-containing extracts or foodstuffs could be used as a 
complementary medicine for the management of nausea/emesis, 
without the side effect usually associated with cannabinoid-based 
antiemetic agents.
ABSORPTiON OF FlAvAN-3-OlS 
AND PACs
Gastric degradation of PC oligomers has been observed after 
their incubation in simulated gastric conditions (pH2) in  vitro 
(71). However, these observations were not confirmed by Rios 
et  al., who investigated the gastric stability of PCs in 6 human 
volunteers after ingestion of cocoa drink containing 733 mg PC 
polymers and 351 mg flavanol monomers. Gastric samples were 
collected through a nasogastric tube every 10  min until total 
gastric emptying (52–60  min), and PCs were quantified. No 
degradation of these molecules was detected, suggesting their 
great stability in the stomach environment, and that most of them 
reach the small intestine intact (72).
Studies in in  vitro models or carried out both in humans 
and animals generally report that PAC monomers, dimers, and 
eventually trimers may be absorbed in the intestine, while larger 
polymers remain unabsorbed and accumulate in the gut lumen 
(73–75). Such absorption is directly proportional to the PACs 
luminal concentrations, as shown in rats by using intestinal per-
fusion of different (+)-catechin concentrations (1–100mM) (76). 
In humans, catechins have been detected in plasma as early as 
30  min after drinking green or black tea (77). The intestinal 
absorption of flavan-3-ols has also been studied in patients with 
ileostomy after the ingestion of 200  mg of a green tea extract. 
About 40% of the flavan-3-ols administered were recovered in 
the ileostomy bag, confirming that substantial amounts of these 
molecules are absorbed in the small intestine (78). In this study, 
sulfate, glucuronide, and methylated conjugated metabolites 
were identified in plasma, all derived from (epi)catechin or (epi)
gallocatechin, representing 47 and 26%, respectively, of the parent 
compounds present in the extract. Data concerning PAC dimers 
are more controversial, and some authors could not detect any 
absorption of these compounds in the intestine. Donovan et al., 
for example, showed that the PAC dimers B1, B2, and B3 were 
not absorbed in rats neither hydrolyzed to their corresponding 
monomers in the intestine (79). The absorption of trimers and 
oligomers is also controversial. Tsang et al. provide evidence that 
PAC oligomers were not depolymerized to monomers to any 
extent after ingestion of a grape seed extract (80). In this study, only 
catechin glucuronides and methylated glucuronide metabolites 
were detected in plasma as well as in the kidneys and liver. These 
metabolites were also found in urine with sulfate metabolites and 
low amounts of the dimers B1, B2, B3, and B4, and the trimer C2. 
In opposition with these results, Shoji et al. detected oligomers 
with a mean DP of 2–5 in rat plasma 2 h after the administration 
of apple PACs with the same DP (81). In another study, 11% of 
ingested PACs from grape seed extract were recovered in feces, 
and 71% of them were tetramers to hexamers, suggesting that 
PACs with more than 3 subunits are more resistant to degrada-
tion and accumulate in the colonic lumen when they may be 
detected in high levels (82). These observations were confirmed 
by Jimenez-Ramsey et  al. and Terrill et  al. using 14C-labeled 
polymeric PACs in chickens and sheep; most of these molecules 
were not absorbed in the intestine of the animals and were widely 
recovered in their feces (83, 84). Similar findings were reported 
in pigs fed grape seed PACs (dimers–pentamers); those were not 
completely absorbed and remained transiting in the gut lumen 
for at least 72 h before their fecal excretion (85). In another study 
in ileostomized subjects, 90% of the PACs consumed as apple 
juice were found in the ileostomy effluent; however, the DP of the 
recovered PACs was reduced to 3.4, in comparison to the initial 
DP of 5.7 in the apple juice. These results, therefore, suggest that 
part of the oligomeric procyanidins were cleaved into smaller 
units that, eventually, were absorbed (86).
From these studies it may be concluded that dietary PACs are 
not affected by their passage across the stomach and that in the 
small intestine, only monomers, dimers, and eventually trimers 
may be absorbed to some extent, while larger oligomers and 
polymers remain in the lumen and accumulate in the colon.
iNTeSTiNAl MeTABOliSM AND 
BiOAvAilABiliTY OF FlAvAN-3-OlS 
AND PACs
Factors other than DP also affect PAC bioavailability. The 
fact that flavanols are frequently acylated, especially by gallic 
acid, reduces their absorption (87) even whether galloylation 
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does not dramatically influence PACs bioavailability as gly-
cosylation with other polyphenols (88). The initial step in the 
intestinal absorption of dietary flavonoid glucosides is their 
deglycosylation, which would occur in the enterocyte brush-
border membrane through the lactase–phlorizin hydrolase 
and beta-glycosidase enzymes (89). This event releases a free 
aglycone that can then enter into epithelial cells either passively 
or by facilitated diffusion (90). However, flavan-3-ols are the 
only subclass of flavonoids present in unglycosylated forms 
in plants, being found naturally as aglycones (91). Therefore, 
the flavan3-ols are absorbed by the enterocytes without any 
deconjugation or hydrolysis (88). On the other hand, flavonoids 
including flavonol-3-ols are generally recognized as xenobiotics 
by the intestinal detoxification system (92). Accordingly, they 
may be subjected to Phase II biotransformation (conjugation) 
in the enterocytes and posteriorly in the hepatocytes, resulting 
in a series of water-soluble conjugated metabolites including 
methyl, glucuronide, and sulfate derivatives (93). The role of 
the small intestine in the glucuronidation and methylation of 
catechins and that of the liver in their sulfation, methylation, 
and biliary excretion has been described in rats by Donovan 
et al. (76). Conjugated compounds are released into the systemic 
circulation for their further distribution to the body organs and 
excretion in urine, or are exported into the bile to come back 
into the intestinal lumen, reaching the colon where they may 
be metabolized by the microbiota or reabsorbed, leading to an 
enterohepatic cycling. After the administration of 500  ml of 
green tea containing 648 µmol of flavan-3-ols in ileostomized 
subjects, Stalmach et  al. quantified the conjugated forms of 
flavanols present in plasma, urine, and ileal effluents. Sixteen 
metabolites were detected in plasma and 18 in urine. In the ileal 
effluents, 70% of the ingested flavan-3-ols were present in their 
native form and 23 metabolites corresponding to conjugated 
forms resecreted into the intestinal lumen were detected, mainly 
sulfate and methyl-sulfate derivatives from epicatechin and 
epigallocatechin (94). Flavanols seem to be present in plasma as 
free flavanols as well as sulfate and glucuronide forms, according 
the type of flavanol (95). In fact, the methylated metabolites of 
catechin, epicatechin, and epicatechin gallate predominate over 
the original unmethylated forms in plasma (96). Lee et al. deter-
mined flavanol conjugates in plasma after ingestion of green tea 
in humans. (−)-Epigallocatechin-3-gallate was mainly detected 
as sulfate conjugate (65%), followed by the free form (20%) and 
glucuronide form (15%), while (−)-epigallocatechin was mostly 
found in the glucuronide form (60%) followed by the sulfate 
form (30%) and the unconjugated (10%). (−)-Epicatechin was 
exclusively found in the conjugated form, with approximately 
two-thirds sulfate and one-third glucuronide (97).
As previously stated, most of the ingested PACs remain 
unabsorbed in the small intestine and accumulate in the colon 
(98) where they are degraded by the colonic microbiota in 
low molecular weight aromatic acids, which differ according 
to their hydroxylation profile and the length of their aliphatic 
side chain (18). These microbial metabolites are absorbed in 
the colon and may be also conjugated by the colonocytes or 
in liver, resulting in glucuronide, methyl, glycine, and sulfate 
derivatives (99).
eFFeCTS OF PACs iN THe DiGeSTiON 
AND ABSORPTiON OF NuTRieNTS
The intestinal lumen is the main site of interactions between 
dietary PACs and nutrients and enzymes. These interactions 
occur thanks to the chemical structure of PACs and their numer-
ous hydroxyl groups suitable for forming non-specific complexes 
with proteins, resulting in their precipitation (100). This event 
occurs preferentially at pH values near the protein isoelectric 
point. Hagerman and Butler have observed that PAC affinity for 
proteins was inversely proportional to protein size and depended 
on their proline content (101). The interaction between PACs 
and proteins constitutes the base of the tanning process that 
transforms animal hides into leather through the complexation 
of skin collagen and the oral sensation of astringency through the 
complexation of salivary proline-rich glycoproteins. Accordingly, 
PACs may also interact with the pancreatic enzymes released in 
the intestinal lumen and with brush-border enzymes and nutri-
ent transporters, thus affecting nutrient bioavailability (102, 103).
effects on the Digestion and Absorption 
of Dietary Carbohydrates
Starch constitutes the main source of carbohydrates and energy in 
the occidental diet, although the disaccharides sucrose and lactose 
and the monosaccharides glucose and fructose are also present 
(104). Starch is digested in the intestinal lumen by pancreatic 
α-amylase and the resulting disaccharides, trisaccharides, and 
limit dextrin are subsequently digested by the brush-border disac-
charidases, maltase-glucoamylase and saccharase-isomaltase, 
while lactose is hydrolyzed by the lactase-phloridzin hydrolase. 
The resulting monosaccharides (glucose, galactose, and fructose) 
are absorbed into the enterocytes through active [sodium–glucose 
cotransporter 1 (SGLT1)] and facilitated [glucose transporter 
(GLUT5 and GLUT2)] apical transporters. Dietary polyphenols, 
including PACs, may delay carbohydrate digestion and reduce 
postprandial glucose absorption, which represents an alternative 
approach for diabetes prevention and management (15, 102).
Inhibition of Enzymes Involved in Carbohydrate 
Digestion
A number of in  vitro studies have evaluated the inhibitory 
activity of different PACs against α-amylase and disaccharidases 
(Table 3). Fractionated polymeric and oligomeric PACs from peel 
persimmon inhibited α-amylase and α-glucosidase in vitro. PAC 
polymers had higher inhibitory activity against α-amylase than 
oligomers, while the opposite was observed against α-glucosidase. 
These results suggest that PAC DP is related to the inhibition of 
these enzymes, and that the oligomers have probably a greater 
potential than polymers for diabetes prevention or management 
(105). In another in  vitro study, aqueous and alcoholic grape 
seed extracts were shown to inhibit α-amylase dose dependently, 
being more elevated the inhibition with the ethanolic extract 
(around 75%) than with the aqueous (around 52%) at the same 
concentration (106). The inhibitory effect of four aqueous extracts 
from different species of cinnamon barks (condensed tannins 
ranging between 0.12 and 0.15 g catechin equivalent/g extract) 
TABle 3 | impact of proanthocyanidins on enzymes involved in carbohydrate digestion.
Type of PACs Type of 
interaction
Model effect Reference
Polymers and oligomers of PACs 
from persimmon peel
Inhibition of 
α-amylase and 
α-glucosidase 
in vitro
PACs concentration: 5, 25, 50, and 
100 µg/ml
Substrate: starch and p-nitrophenyl 
α-D-glucopyranoside (pNPG)
Inhibition of α-amylase: 53.9% polymers; 4.6% 
oligomers (at 100 µg/ml)
Inhibition of α-glucosidase: 74% polymers; 97.4% 
oligomers (at 100 µg/ml)
(105)
Water grape seed extract 
(WGSE, 26.7 mg PACs/g) and 
ethanol grape seed extract 
(EGSE, 32.6 mg PACs/g) of red 
grape seeds
Inhibition of 
α-amylase in vitro
Extract concentration: 400, 800, 
1,300, and 1,800 ppm
Substrate: starch
Inhibition of α-amylase: 74.86% EGSE; 52.48% 
WGSE (at 1,800 ppm) (enzyme preincubated with 
extract)
(106)
Four aqueous extracts from 
cinnamon bark (condensed 
tannins ranged between 
0.12 and 0.15 g catechin 
equivalent/g extract)
Inhibition of 
α-amylase and 
α-glucosidase 
(maltase and 
sucrase) in vitro
Extract: Chinese, Ceylon, Saigon, 
and Thai cinnamon extracts (CEs)
Substrate: starch, maltose, sucrose
Inhibitory activity [IC50 (mg/ml)]
α-amylase: > Ceylon (1.23 mg/ml) < Saigon 
(>4 mg/ml)
Maltase: > Thai (0.58 mg/ml) < Saigon (1.96 mg/ml)
Sucrase: > Ceylon (0.42 mg/ml) < Saigon (>4 mg/ml)
(107)
Pycnogenol® [65–75% 
procyanidins (PCs)]
Inhibition of 
α-glucosidase 
in vitro
Extract: pycnogenol® compared 
with acarbose and green tea 
extract (both positive controls)
Substrate: p-nitrophenyl α-D-
glucopyranoside (pNPG)
Inhibitory activity [IC50 (μg/ml)]
Pycnogenol® (5.34 µg/ml) > green tea extract 
(19.74 µg/ml) > acarbose (1,010 µg/ml)
(108)
PACs from peanut skin extract (9 
acetone fractions)
Inhibition of 
maltase and 
sucrase in vitro
Extract concentration: 1 mg/ml
Substrate: maltose and sucrose
Inhibitory activity [IC50 (mg/ml)]
Against maltase: epicatechin-
(2β → O → 7,4β → 8)-[catechin-(6 → 4β)]-
epicatechin (0.088 mg/ml) (trimeric PAC)
Against sucrase: epicatechin-(4β → 8)-epicatechin-
(2β → O → 7,4β → 8)-catechin (0.091 mg/ml) 
(trimeric PAC)
(110)
Condensed tannins from 
cranberry, grapes, and cocoa 
extracts
Inhibition of 
α-amylase and 
glucoamylase 
in vitro
Extract: different tannin:enzyme 
ratio
Substrate: starch and maltose
Inhibitory activity (%):
Against α-amylase (ratio 1:1): cocoa (14%); grape 
(28%); cranberry (55%)
Against glucoamylase (ratio 0.01:1): cocoa, grape, 
and cranberry ~20%
Against glucoamylase (ratio 1:1): cocoa (23%); 
grape (55%); cranberry (41%)
(103)
Octa-decyl silyl silica gel eluted 
fraction of polyphenols from 
peanut seed skin (39% PCs) 
and almond seed skin (30% 
PACs)
Inhibition of 
α-amylase and 
α-glucosidase 
in vitro
Substrate: starch, maltose, and 
sucrose
Peanut seed skin inhibitory activity  
(U/mg dry weight): α-amylase: 169; maltase: 4.41; 
sucrase: 4.69
Almond seed skin inhibitory activity [IC50 (μg/ml)]: 
α-amylase: 2.2; maltase: 468; sucrase: 627
(111, 112)
Cacao liquor PACs (CLPr) Prevent elevation 
of blood glucose 
levels
Mice with diabetes mellitus and 
obesity (db/ob) feed with 0.5 and 
1% of CLPr
↓ blood glucose levels at 4 and 5 weeks of age 
(1% CLPr) and 5 weeks of age (0.5% CLPr), 
compared with controls
(114)
PACs oligomers of 
persimmon leaf  
tea (PaW-PP)
Inhibition of 
α-amylase and 
maltase in vitro
Blood glucose 
levels in rats
PaW-PP concentration: 240 µg/ml
Substrate: starch and maltose
Oral carbohydrate tolerance test: 
soluble potato starch (2.0 g/kg 
of body weight) and 1.0 ml of 
aqueous solution of PaW-PP (0, 
100 or 300 mg/kg of body weight)
Inhibitory activity:
64% on α-amylase; 5.2% on maltase
↓ blood glucose levels at 30, 120, and 180 min after 
100 mg/kg and in all time points after 300 mg/kg
(115)
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against α-amylase, maltase, and sucrase activities was determined 
in vitro. Thai cinnamon was the most potent maltase inhibitor 
and Ceylon cinnamon the most efficient in suppressing sucrase 
and α-amylase. When combined with acarbose (a recognized 
α-glucosidase inhibitor), all the extracts displayed an additive 
inhibition against α-amylase, while only the Chinese, Ceylon, 
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and Thai cinnamon extracts (CEs) showed an additive inhibition 
against sucrase and maltase (107). Interestingly, these results 
suggest that PACs from the same botanical species may differ in 
their PAC composition depending on the geographical origin of 
the plant, probably due to differences in geo-climatic conditions 
of culture. Pycnogenol® was also shown to inhibit baker’s yeast 
α-glucosidase more efficiently than green tea extract and acarbose. 
This could explain the glucose-lowering effects reported with this 
product in clinical trials with diabetic patients (108, 109). PAC 
fractions purified from peanut skin also showed an inhibitory 
activity against maltase and sucrase at a concentration of 1 mg/
ml. The strongest maltase inhibition was exerted by the trimeric 
PAC epicatechin-(2β →  O →  7,4β →  8)-[catechin-(6 →  4β)]-
epicatechin, while the strongest sucrase inhibition was exhibited 
by another trimeric PAC, epicatechin-(4β  →  8)-epicatechin-
(2β → O → 7,4β → 8)-catechin. The inhibitory activity of both com-
pounds was lower than acarbose but higher than that of dimeric 
PACs (110). Barrett et al. studied the effect of condensed tannins 
from cranberry, grapes, and cocoa extracts against α-amylase 
and glucoamylase in vitro, using different tannin:enzyme ratios 
(0.01:1 to1:1) (103). Cocoa, grape, and cranberry tannins exerted 
the highest inhibition of α-amylase and glucoamylase at 1:1 ratio 
(14, 28, and 55%, respectively, for α-amylase and 23, 55, and 41% 
respectively for glucoamylase). Cocoa, cranberry, and grape tan-
nins also reduced glucoamylase activity in approximately 20% at 
the 0.01:1 ratio. Grape and cranberry increased their inhibitory 
activity against the enzyme at 1:1 ratio (55 and 41%, respectively). 
Accordingly, in this study, the inhibitory effect was strongly 
dependent on the tannin concentration and HMW tannins (like 
those present in cranberries) have greater inhibitory capacity 
than LMW tannins (like those present in cocoa). Similar findings 
were also described by Tsujita et  al. with different fractions of 
peanut seed skin (111) and almond seed skin (112).
Only one study has evaluated the effect of dietary PACs on 
lactase activity showing that tea epigallocatechin-3-gallate inhib-
its lactose hydrolysis by intestinal lactase in vitro (IC50 74µM) at 
physiological luminal concentrations (113).
Although a great number of studies evaluated the effect of 
PACs on pancreatic amylase and disaccharidases, most of them 
were carried out in vitro and have inherent limitations due to 
the use of porcine or yeast enzymes, whose specificity may differ 
from these of human origin, and to the method employed for 
quantifying the enzymatic activity. For example, synthetic sub-
strates are frequently used, that may be affected by the presence 
of PACs. In addition, they ignore the presence of other proteins 
normally present in the GI tract, like salivary proline-rich 
proteins, which may interfere with the inhibition of enzymes 
by PACs (102).
In vivo studies evaluating the interaction between PACs and 
the enzymes involved in carbohydrate digestion are scarce. 
Tomaru et al., for example, observed that dietary supplementation 
of diabetic obese mice with 0.5 or 1.0% cacao PACs [containing 
2.49% catechin, 5.89% epicatechin, 3.93% PC B2, 2.38% PC C1, 
3.17% cinnamtannin A2, and 0.48% galactopyranosyl-ent-(−)-
epicatechin-(−)-epicatechin] dose dependently prevented the 
development of hyperglycemia (114). The administration of PAC 
oligomers from persimmon leaf tea to Wistar rats significantly 
decreased their blood glucose levels when compared with the 
placebo group (115).
Inhibition of Monosaccharide Transporters
The intestinal absorption of the monosaccharides resulting from 
starch and disaccharide digestion is mediated by transporters 
located in the brush-border membrane, on the apical side of the 
enterocytes. SGLT1 is an electrogenic transporter that depends 
on the Na+ gradient and mediates the absorption of glucose 
and galactose into the enterocyte (15, 102, 116). SGLT1 has a 
high affinity but a low transport capacity for glucose. GLUT5 
is a facilitated transporter involved in fructose absorption (102, 
116, 117), while GLUT2 is a facilitated transporter for glucose, 
galactose, and fructose; contrarily to SGLT1, it has low affinity 
but high transport capacity for glucose. GLUT2 was first located 
in the enterocyte basolateral membrane where it mediated the 
exit of the monosaccharides present in the cells to the systemic 
circulation during the postprandial period (118). More recently, 
the presence of GLUT2 has been described in intracellular vesi-
cles. When the intraluminal concentration of glucose increases, 
i.e., after the intake of a meal rich in carbohydrates, GLUT2-
containing vesicles translocate to the apical membrane where 
it contributes to glucose and fructose absorption. It has been 
proposed that two-third of the total amounts of glucose absorbed 
by the intestine in the postprandial period is through GLUT2. 
GLUT2 would be reinternalized in the cytoplasmic vesicles when 
the luminal concentration of glucose decreases or through insulin 
regulation (15, 102, 118–120).
The role of polyphenols in the regulation of the apical trans-
porters has been widely studied (121–127). Several compounds 
have been shown to interfere with these transporters such as 
berry anthocyanins, apple polyphenols (phlorizin, quercetin, 
kaempferol, phloretin, and chlorogenic acid), helichrysum, and 
grapefruit (kaempferol-3-O-glucoside, chlorogenic acid-3-O-
glucoside, naringenin-7-O-glucoside, naringenin diglycoside, 
kaempferol rutinoside, naringenin-7-O-rutinoside, and querce-
tin monoglucosides, among others) (121–126). Although the 
effect of PACs on these transporters was not evaluated so far, 
it is possible that they may exert certain activity, since flavanol 
monomers such as catechin, epicatechin, epigallocatechin, epi-
catechingallate, and epigallocatechingallate have been shown to 
inhibit SGLT1 or GLUT2 (128, 129). Kobayashi et al. observed 
that epicatechingallate and epigallocatechingallate (1mM) from 
tea reduced glucose uptake by rabbit brush-border membrane 
vesicles by 53 and 35%, respectively, whereas the inhibitory effects 
of catechin and epigallochatechin were not significant (128). In 
another study, all these flavanol monomers were shown to inhibit 
SGLT1-mediated glucose transport into Caco-2 cells (129).
effects on the Digestion and Absorption 
of Dietary lipids
Triglycerides (TG) constitute the majority of the dietary lipids, 
while the contribution of cholesterol (CS) and phospholipids 
is much lower. Due to their hydrophobicity, lipids must be 
solubilized to be digested and posteriorly absorbed (130). Dietary 
fats are first emulsified in the stomach, a phenomenon that 
increases the rate of TG hydrolysis by the lipase and the release of 
TABle 4 | impact of proanthocyanidins on enzymes and transporters involved in the digestion and absorption of lipids.
Type of PACs Type of interaction Model effect Reference
Water grape seed extract 
(WGSE, 26.7 mg PACs/g) 
and ethanol grape seed 
extract (EGSE, 32.6 mg 
PACs/g) of red grape seeds
Inhibition of 
pancreatic lipase (PL) 
in vitro
Extract concentration: 400, 800, 
1,300, and 1,800 ppm
Substrate: olive oil emulsion
Inhibition of lipase:
52.66% EGSE; 45.44% WGSE (at 1,800 ppm) (enzyme 
preincubated with extract)
61.41% EGSE; 42.63% WGSE (at 1,800 ppm) 
(substrate preincubated with extract)
(106)
Apple polyphenol extract 
(AP) and the procyanidins 
(PCs) contained in the 
extract
Inhibition of PL in vitro Substrate: 4MUO Inhibition of lipase [IC50 (μg/ml)]: PCs (1.4 µg/ml) > AP 
(5.6 µg/ml) > other polyphenol fraction (115.9 µg/ml)
(135)
Triglyceride (TG) 
absorption in mice
1,000 mg/kg of AP compared 
with control (water) and 10 ml/kg 
body weight of corn oil
AP completely prevent the increase of plasma TG level
TG absorption in 
humans
600 mg of AP and 40 g of TG Inhibition of TG elevation at 6 h after ingestion
Cocoa (PCs) (>85% purity) 
[degree of polymerization 
(DP) between 2 and 10]
Inhibition of PL 
and secreted 
phospholipase A2 
(PLA2) in vitro
PL: PCs: 0–20µM and 4-NPB as 
substrate. Orlistat as control
PLA2: PCs: 0–100μM and Red/
Green BODIPY PC-A2, 1.67µM as 
substrate
PCs with DP ≥ 5 inhibited PL by 37 to 53% at 20µM. 
Orlistat 72% at 10µM
PCs with DP between 2 and 5 inhibited PLA2 by 
46–74% at 100µM
PCs with DP between 6 and 10 inhibited PLA2 by 
approximately 90% at 50µM (IC50 < 5µM)
(136)
Tannins from persimmon Capacity to bind 
primary and 
secondary bile acids 
in vitro and in vivo
Tannins concentration: 1% (w/v). 
Bile acids concentration: 1 mM 
solutions. Cholestyramine positive 
control
Tannins adsorbed approximately 80% of all bile acids 
(cholic, taurocholic, glycocholic, and deoxycholic acid), 
similar to a cholestyramine
(138)
Mice supplemented for 14 days 
with a tannins diet [1% (w/w)] 
Cholestyramine as positive control
Tannin supplementation: twofold more excretion of 
bile acids in feces compared with a control (without 
supplementation)
Grape seed extract (GSE, 
49.8% PCs)
Inhibition of PL GSE 4.75–0.62 mg/ml. Orlistat as 
positive control
Inhibitory activity: GSE (IC50 44.5 mg/ml); Orlistat (IC50 
3.7 mg/ml)
(139)
Inhibition of 
pancreatic cholesterol 
(CS) esterase
GSE 50–3.12 µg/ml. Simasvatin 
as positive control
Inhibitory activity: GSE (IC50 27.27 µg/ml); Simasvatin 
(IC50 0.08 µg/ml)
Effect on CS 
micellization
GSE at 10, 20, and 40 mg/ml on 
artificially micelles. Gallic acid as 
positive control
Inhibition of CS solubility: gallic acid (27.26%) > GSE 
40 mg/ml (11.87%) > GSE 20 mg/ml (6.84%) > GSE 
10 mg/ml (3.18%)
(Continued )
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diacylglycerol and free fatty acids (FFAs). Once in the small intes-
tine, the fat emulsion is stabilized by bile salts, enabling the action 
of the colipase/pancreatic lipase (PL), CS ester hydrolase, and 
phospholipase A2 (PLA2) (130). PL hydrolyzes the TGs, releasing 
the fatty acids esterified in the carbon 1 and 3 of the molecule, and 
monoacylglycerol. Regarding CS ester hydrolase and PLA2, these 
enzymes hydrolyze CS esters and phospholipids, releasing free CS, 
FFAs, and lysolecithin (130). As these final products of digestion 
(monoglycerides, FFAs, CS, and lysolecithin) are hydrophobic, 
they must be incorporated into biliary mixed micelles as they are 
released in the lumen. This process of solubilization allows them 
to diffuse across the unstirred water layer until the enterocyte sur-
face, where they are released from the micelles. Posteriorly, they 
enter into the absorptive cells by passive diffusion according their 
concentration gradient or by using specific transporters such as 
FAT/CD36, FATP4, and FABPpm for FFAs and Niemann–Pick 
C1-like protein 1 (NPC1L1) for CS (131, 132). In the enterocytes, 
FFAs are reesterified with glycerol or CS, and the resulting TG 
and CS ester are subsequently incorporated to chylomicrons 
and exported into lymphatic circulation, to finally end up in 
the bloodstream. Bile salts are reabsorbed in the terminal ileum 
through the apical sodium bile acid transporter, they reach the 
circulation and are taken up by the liver and resecreted by the 
biliary system. This enterohepatic circulation takes place 10 times 
per day so that less than 5% of bile acids enter the large intestine 
during this period for fecal elimination (133).
Similar to carbohydrates, the enzymes and transporters 
involved in lipid digestion and absorption are subjected to the 
action of dietary polyphenols. Most of the studies have focused 
on the inhibitory activity on of these compounds on PL, PLA2, 
or bile salts, due to their implication in fat absorption and their 
potential to prevent obesity and its complications. Fewer stud-
ies have focused on their interaction with CS esterase or lipid 
transporters (Table 4).
Type of PACs Type of interaction Model effect Reference
Capacity to bind bile 
acid
GSE 1 mg/ml. Bile acid 2 mM. 
Cholestyramine as positive control
% Bile acid binding: glycodeoxycholic 
(70%) > taurocholic (25%), both similar to 
cholestyramine. Taurodeoxycholic acid was slightly 
bound
Serum TG and CS 
concentrations
Oral administration of 5 ml/kg 
body weight of olive oil emulsion 
(3.33 ml of olive oil, 44.3 mg of 
cholic acid, 0.48 g of CS, and 
1.67 ml of distilled water)
GSE: 100, 250, and 500 mg/kg
↓ in serum TG concentrations (2–6 h after 
administration) at 250 and 500 mg/kg GSE [area under 
the curve (AUC) 19 and 27% lower than control group, 
respectively]
Suppression of the increase in serum CS concentration 
(after 4 h of loading fat emulsion) at 250 and 500 mg/
kg (AUC 8 and 11% lower than in control group, 
respectively)
Aqueous CE
(4.1% type-A polymers)
Expression of genes 
of Niemann–Pick 
C1-like protein 1 
(NPC1L1) and CD36
Enterocytes treated with 10 or  
100 µg/ml of CE for 0, 0.5, 2, 
and 4 h
↓ NPC1L1 mRNA at 2 h (10 µg/ml) and at 4 h (100 µg/
ml)
↓ CD36 mRNA at 4 h (10 µg/ml) and at 0.5 h (100 µg/
ml)
(140)
Grape seed 
proanthocyanidin extract 
(GSPE)
Intestinal expression 
of NPC1L1 and CD36
Rats fed with lard (2,5 ml/kg of 
body weight), supplemented or 
not with GSPE (250 mg/kg of 
body weight)
Lard induces a decrease in the expression of all 
genes evaluated. GSPE do not induce changes in the 
expression of genes
(141)
Polyphenol extracts 
from grape (41% PACs), 
cranberry (32% PACs), 
avocado (29% PACs), and 
apple (22% PACs)
Inhibitory activity on 
PL in vitro
Lipase: 2 mg/ml. PACs extracts: 
0; 0.065; 0.125; 0.25; 0.5; and 
1 mg/ml. Substrate: 4-MUO 
(4-metilumbeliferil oleate) (0.1mM)
Inhibitory activity:
Grape > cranberry > avocado > apple
(137)
Plasma TG 
concentrations in vivo
Subjects: normal weight (NW) and 
overweight/obese (OW/Ob)
Extract: 1 g of extract or placebo
High-fat test meal: 63 g fat
Absorption of TG was 2 times higher in the OW/Ob 
than in the NW subjects and was unaffected by the 
treatment
TABle 4 | Continued
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Inhibition of Enzymes Involved in Lipid Digestion
Hassan reported that an ethanol extract from grape seed was 
more efficient than a water extract in inhibiting TG hydrolysis 
by PL in  vitro when they were preincubated with the enzyme 
(52.7 vs 45.4%, respectively) or with its substrate (61.4 vs 42.6%, 
respectively). Such effect was related to the PACs content of the 
extracts (106). An apple polyphenol extract containing 65.7% 
PCs and 12.5% flavan-3-ols almost completely inhibited PL 
activity in a dose-dependent manner (134). The purified PC 
fraction showed the higher inhibitory activity, compared to the 
other polyphenols fractions, and the effect was mainly associated 
with the DP [DP ≥ 5 had the highest inhibitory activity, espe-
cially the heptamer fraction (IC50 = 0.7 μg/ml)]. Results in mice 
indicate that 1,000 mg/kg of the apple extract fully prevented the 
increase of plasma TG after the administration of 10 ml corn oil/
kg body weight, compared to the control group. In humans, the 
elevation of postprandial plasma TG was significantly inhibited 
after the intake of 600  mg apple extract together with 40  g 
dietary fat (135). In another study, the effect of purified cocoa 
PCs (>85%; DP between 2 and 10, B-type) against PL and PLA2 
was determined in vitro. PCs with DP ≥  5 inhibited PL, while 
those with a DP between 2 and 5 inhibited PLA2, and those with 
DP between 6 and 10 inhibited PLA2 by approximately 90% at 
50µM (136). The authors conclude that cocoa PCs has higher 
inhibitory activity against PLA2 than against PL and suggest that 
DP is an important factor in determining the potency of these 
compounds. We recently compared the lipase inhibitory effect 
of PAC-containing polyphenol extracts from grape, cranberry, 
avocado, and apple (137). The most to least efficient extracts 
were grape > cranberry > avocado > apple. The strongest lipase 
inhibitory activity was exerted by the extract with the higher PAC 
content and higher DP (9.8) and the only ones containing galloyl 
moieties. Accordingly, we observed that the PAC content of the 
extracts correlated (r = 0.85; p < 0.001) with their lipase inhibi-
tory activity, and a similar correlation was also observed when 
considering the PAC DP. However, when 1 g of the grape extract 
was administered to normal-weight or overweight/obese sub-
jects simultaneously with a high-fat breakfast, the postprandial 
increase of plasma TG was not affected compared to the placebo 
(137). It is important to consider that in humans, PL is released 
in excess into the intestinal lumen and that, independently of the 
inhibitory activity exhibited by the extract in  vitro against this 
enzyme, the amounts of PACs ingested may be insufficient to 
inhibit the enzymatic activity completely.
Another interesting target for PACs to inhibit lipid absorption 
is bile salts. Matsumoto et al. (138) investigated the ability of per-
simmon tannins to bind primary and secondary bile acids in vitro 
and in vivo. These PACs had a high DP and were composed by 
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epicatechin, epigallocatechin, epicatechin-3-O-gallate, and 
epigallocatechin-3-O-gallate. At a concentration of 1% (w/v), 
PACs adsorbed approximately 80% of the primary and secondary 
bile acids in vitro, similar to cholestyramine. In mice fed a diet 
supplemented with 1% persimmon tannins for 14 days, a twofold 
increase of fecal bile salt excretion was observed, compared to 
the control, not supplemented, group. However, this increase 
remained lower than that observed in the animals treated with 
cholestyramine. Such interference with bile salts might affect the 
stabilization of fat emulsion in the intestinal lumen, and/or the 
formation of biliary micelles.
A grape seed extract (49.8% PCs) was shown to inhibit PL 
and CS esterase activities, but less than their respective positive 
controls, orlistat and simvastatin. To study the effect of the extract 
on CS micellization, the authors evaluated the solubility of CS in 
artificially prepared micelles in presence of different concentra-
tion of the extract. They observed a decrease of CS solubility, but 
less than with the positive control gallic acid (139). With respect 
to bile acid binding capacity, the extract binds strongly glycold-
eoxycholic and taurocholic acids (70 and 25%, respectively) at a 
concentration of 1 mg/ml, similar to the effect of cholestyramine 
at the same concentration. Rats fed a high-fat emulsion with 250 
or 500  mg/kg extract showed a significant diminution in the 
postprandial plasma TG concentrations between 2 and 6  h, as 
reflected by changes in the area under the curve (AUCTG) (19 
and 27% lower than the control group). At these same doses, 
the extract significantly suppressed the postprandial increase 
in serum CS concentrations (AUC 11% lower than the control 
group). It is therefore possible that this extract can be used as 
therapeutic strategy to prevent hyperlipidemia and obesity due 
to its capacity to improve plasma lipid profile.
Inhibition of Lipid Transporters
A number of studies have focused on the interactions between 
polyphenols and intestinal lipids transporters. An aqueous CE 
containing PACs (4.1% type-A polymers) has been shown to 
decrease the mRNA levels of CD36 (a FFA transporter) and 
NPC1L1 (implicated in the intestinal uptake of CS) in small 
intestine enterocytes (140). In opposition to these results, 
Quesada et al. did not report any effect of a grape seed extract 
on the expression of these transporters in rats fed a diet with 
lard (141).
Inhibition of Lipopolysaccharide (LPS) Absorption
In our previously described study (137), we also address the capac-
ity of PACs to bind bacterial LPS, as previously by described by 
Delehanty et al. (142). In fact, it has been proposed that LPS from 
intestinal Gram-negative bacteria could enter the enterocytes 
and be incorporated into the chylomicrons to be excreted to the 
lymphatic system and bloodstream. Accordingly, the presence of 
dietary lipids in the intestinal lumen would stimulate LPS absorp-
tion and, eventually the development of metabolic endotoxemia 
(143, 144). We confirm that the grape extract bound LPS in vitro, 
inhibiting its union to polymyxin B and that, when administered 
to the volunteers after the high-fat meal, it significantly decreased 
the elevation of postprandial plasma LPS associated with that of 
TG in the volunteers (137). This phenomenon constitutes a new 
mechanism by which PACs may decrease systemic inflammation.
In conclusion, some evidence exist that dietary PACs interfere 
with the different events involved in intraluminal lipid process-
ing, including enzymatic hydrolysis, micellization, and uptake of 
lipid digestion products by the intestinal epithelial cells. However, 
most of the studies have focused on the interaction between PACs 
and PL in vitro and, in some cases, in animal models, which do 
not accurately represent the situation occurring in the organism. 
Considering these points, further studies are necessary to eluci-
date the role of PACs in intestinal fat digestion and absorption 
in humans.
effects on the Digestion and Absorption of 
Dietary Proteins
The digestion of dietary protein occurs first in the gastric and 
intestinal lumen through the action of HCl/pepsin and pancreatic 
proteases, including pepsin, trypsin, chymotrypsin, elastase, 
carboxypeptidase A, B, and aminopeptidase, and concludes with 
peptidases located in the brush-border membrane and cytoplasm 
of the enterocytes (130, 145). Pepsin and pancreatic proteases 
hydrolyze proteins in amino acids, di-, tri-, and oligopeptides. 
Posteriorly, amino acids are absorbed into the enterocytes through 
specific transporters according to their chemical structure 
(146), while di- and tripeptides are transported by the proton-
dependent cotransporter, Pept-1 (130, 147). Oligopeptides need 
further hydrolysis by brush-border proteases to yield absorbable 
molecules (130). In the absorptive cells, the di- and tripeptides are 
hydrolyzed to amino acids by cytosolic peptidases, and these are 
exported to the bloodstream by facilitated diffusion (130).
Inhibition of Enzymes and Transporters Involved in 
Protein Digestion and Absorption
As previously stated, PACs display a high affinity for proteins, 
particularly for these with high-proline content. Accordingly, 
they may affect the bioavailability of dietary proteins by decreas-
ing their digestibility, either directly by binding them or indirectly 
by inhibiting enzymatic activities (Table  5). These processes 
contribute to the fact that condensed tannins are sometime 
considered as antinutritional factors.
A maximal inhibitory activity of trypsin in vitro was reported 
for grape seed PACs at a concentration of 313  mg/l; the enzy-
matic inhibition correlated with PC DP (148). In another study, 
the same authors investigated the mechanism by which trypsin 
is inhibited by PC dimer B3 (149). They reported that, at low 
concentration, specific interactions mediated by hydrogen bonds 
occur between the hydroxyl groups of the dimer and the amide 
and carbonyl group of the protein backbone, while at high 
concentration, those interactions were not specific. Horigome 
et al. also reported a positive correlation between the PAC DP 
of four fodder plants and their capacity to precipitate proteins 
and inhibit trypsin activity (150). In addition, they observed that 
the preincubation of bovine serum albumin with PACs inhibited 
its digestion. Rats fed a tannin supplemented diet (10 g/kg) dis-
played a significantly reduced trypsin activity in their intestine. 
When antibiotic treated rats (to eliminate the effect of bacterial 
TABle 5 | impact of proanthocyanidins on enzymes and transporters involved in the digestion of proteins.
Type of PACs Type of interaction Model effect Reference
Oligomeric procyanidins 
(OPC) of grape seed
Inhibition of trypsin 
in vitro
Trypsin: 0.072 g/l
Substrate: BApNA
OPC at 313 mg/l had the highest inhibitory activity. At 233 mg/l 
fractions 4 and 5 had the higher inhibitory activity
(148)
Condensed tannins 
from 4 fodder plants 
(PACs from oligomer to 
octamer)
Inhibition of trypsin 
in vitro and in vivo
Substrate: BApNA
Rats feed with tannin 
containing diet (10 g/kg)
Positive correlation between degree of polymerization and 
inhibitory activity on trypsin (r = 0.928) and protein precipitation 
capacity (r = 0.855)
↓ in activity of trypsin in the upper, middle, and lower segments of 
intestine
(150)
Procyanidins from grape 
seed
Inhibition of 
pancreatic elastase 
in vitro
Pancreatic elastase 
(PPE) (0.8 µM), Suc-
(Ala)3-p-nitroanilide 
(250 µM) as substrate
Inhibitory activity:
Oligomeric fraction: IC50 16 µM
Tetramer fraction: IC50 585.1 µM
Trimer C2: IC50 5,863.3 µM
(151)
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enzymes) were fed with a tannin supplemented diet (20 g/kg), 
they observed a significant decrease in nutrient digestibility. 
Based on these results the authors conclude that the formation of 
insoluble enzyme–tannin complexes is responsible of the inhibi-
tion of trypsin activity. Brás et al. studied the effect of dimer B3, 
trimer C2, tetramer, and oligomer fractions of PCs on pancreatic 
elastase activity. The inhibitory activity increased with the PCs 
molecular weight, being the oligomer fraction the most potent 
inhibitor (approximately 90%; IC50 =  16μM) (151). In another 
study, these authors reported that elastase, in the presence of PCs, 
undergoes slight changes in its secondary (R-helix to β-sheet) and 
tertiary structures, and forms insoluble aggregates (152).
Fewer studies have addressed the influence of PACs on the oth-
ers enzymes involved in protein digestion. Uchida et al. showed 
that the inhibitory activity of condensed tannins from Rhei 
Rhizoma against the angiotensin converting enzyme increased 
with the PACs DP (153). The PC B-5 3,3′-di-O-gallate had the 
highest angiotensin converting enzyme inhibitory activity, and 
the authors indicate that this activity was protein-specific as this 
PACs did not inhibit other enzyme activities such as trypsin, 
chymotrypsin, leucine aminopeptidase, carboxypeptidase A, and 
urinary kallikrein. No studies were found regarding the interac-
tion between PACs and intestinal amino acids and peptides 
transporters.
The fate of the PAC-bound proteins in the intestinal and 
colonic lumen remains unclear. An increased flux of indigested 
proteins in the colon may result in a major production of toxic 
metabolites derived from their fermentation by the intestinal 
microbiota (IM), with negative consequences to the host (154). 
However, PACs are used in ruminant nutrition to reduce protein 
degradation in the rumen (155), and it is possible that this phe-
nomenon also occurs in the human colon. PAC-bound proteins, 
therefore, should be eliminated in stools.
eFFeCTS OF PACs iN DiARRHeA AND Gi 
MOTiliTY
Cássia Santos et al. evaluated the effect of a methanolic extract 
from leaves of B. intermedia containing catechin derivatives and 
oligomeric PACs in a rodent model of castor oil-induced diar-
rhea. The extract was shown to prevent or revert the diarrhea, 
decreasing fluid accumulation and the emission of watery stools, 
probably through the stimulation of intestinal opioid receptors, 
without affecting intestinal motility (156). In a similar study, a 
fraction from Chiranthodendron pentadactylon flowers rich in 
flavan-3-ols was evaluated using rat jejunal loops exposed to 
cholera toxin (3 µg). (−)-Epicatechin showed the best antisecre-
tory activity (ID50 =  8.3 μm/kg), like that of the antisecretory 
drug loperamide (ID50 = 6.1 µm/kg), and better than (+)-catechin 
(ID50 = 51.7 μm/kg) and other compounds presents in the extract 
(flavonol glycosides). Such observations support the traditional 
use of C. pentadactylon flowers in the treatment of dysentery in 
the Mexican traditional pharmacopeia (157). In another study, 
the effect of Aronia melanocarpa fruit juice (rich in condensed 
tannins) was shown to significantly reduce the intestinal transit 
in charcoal-administered rats (158). Interestingly, a patent (No 
US 7,341,744 B1) “Method of treating secretory diarrhea with 
enteric formulations of proanthocyanidins polymer” was recently 
registered by Rozhon et  al. that describes the pharmaceutical 
formulation of a proanthocyanidin polymer isolated from Croton 
spp. or Calophyllum spp., useful for the treatment and prevention 
of secretory diarrhea (159).
THe PACs iN THe COlON
The human colon harbors a highly complex microbial ecosystem 
that includes bacteria, yeasts, fungi, virus, and phages. More 
than 1,000 species of bacteria have been described, most of them 
anaerobic, and with counts reaching 1011–1012/g of intracolonic 
content (160–166). These microorganisms express a great 
number of enzymes capable of metabolizing the majority of the 
substrates reaching the colon, including xenobiotics and PACs 
(167). The gut microbiota exhibits metabolic, nutritional, and 
protective functions important for the host health (161, 165). 
It is involved in energy salvage from the dietary compounds 
non-digested and absorbed in the small intestine, vitamin 
synthesis, and in the metabolism of bile salts and xenobiotics. 
The IM also exerts a protective function, decreasing the risk 
of pathogen overgrowth in the colonic lumen, stimulating the 
local immune system and contributing to the development of 
oral immune tolerance (154, 161, 163). The dominant bacterial 
phyla constituting the IM are Firmicutes and Bacteroidetes 
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and, in lower proportions, Proteobacteria, Actinobacteria, and 
Verrucomicrobia (164, 165), while the main bacterial genera are 
Clostridium, Bacteroides, Prevotella, Eubacterium, Ruminococcus, 
Fusobacterium, Peptococcus, and Bifidobacterium (160). Some 
genera are more particularly considered as beneficial for the 
host like Bifidobacterium, Lactobacillus, Faecalibacterium 
prausnitzii (a butyrate-producing bacteria), and Akkermansia 
muciniphila, while others are considered as potentially harm-
ful like Staphylococcus, some species of the Clostridium genus 
(C. perfringens, C. difficile) and Pseudomonas, which have been 
associated with diarrhea, systemic infections, liver damage, can-
cer, and encephalopathy (162). Among the numerous metabolites 
produced by the IM, the most widely studied are those produced 
by the fermentation of the dietary fiber in the colon, i.e., the short 
chain fatty acids (SCFAs) acetate, propionate, and butyrate (161). 
The decrease of colonic luminal pH induced by SCFAs reduces 
the risk of pathogen overgrowth and improves mineral solubility 
and absorption (163). They also act, promoting the integrity of 
the gut barrier function and host satiety (168). Butyrate is also 
considered as a preferential substrate for the colonocytes; in 
addition, it exerts antiinflammatory and antitumoral activities, 
this latter by favoring the differentiation and apoptosis of epi-
thelial cells. Regarding acetate and propionate, they have been 
implicated in the regulation of lipid metabolism in the liver (161, 
163). However, some of the metabolites produced by the colonic 
fermentation of amino acids including ammonia, hydrogen 
sulfide, indol, and phenol compounds, among others, can exert 
deleterious effects on the colonic mucosa and host health. Indeed, 
these metabolites affect colonocyte oxidative metabolism and 
cellular respiration, produce genomic DNA damage, affect the 
integrity of the barrier function, and also act like pro-carcinogens 
and promoters of colorectal cancer as well as inflammatory bowel 
diseases (IBD) (154, 165, 169).
The composition of the IM is influenced by many factors 
such as the age, gender, and genetic background of the host, the 
consumption of xenobiotics, antibiotic, and other drugs, the 
existence of physical or psychological stress, environmental and 
dietary factors, this latter being probably the most important 
(160, 161, 164). Accordingly, probiotics and prebiotics have been 
typically used as a strategy for the nutritional management of 
the IM composition and its metabolic/immunological activities 
(165, 170).
effect on the iM
As described above, a great proportion of the dietary polyphenols, 
including PACs, remain undigested in the intestine and reach 
the colon, where they are used as substrates by specific bacterial 
populations, stimulating their growth much like prebiotics do. In 
addition, PACs with high DP exert bacteriostatic and eventually 
bactericide effects that might also contribute to the modulation of 
IM composition and bacterial adhesion to colonocytes (164, 171).
Several studies have investigated the effect of PAC intake 
on the composition of the IM. In an in  vitro model of colonic 
fermentation, the addition of (+) catechin (150  mg/l) for 48  h 
increased significantly the growth of C. coccoides–E. rectale group, 
Bifidobacterium spp., and E. coli and inhibited that of C. histolyti-
cum. In the same conditions, the incubation with epicatechin only 
increased the growth of C. coccoides–E. rectale group (172). In a 
similar model, a grape seed extract with 28% PACs (600 mg/l) 
promoted the growth of Lactobacillus/Enterococcus group at 5 and 
10 h, while the extract with 78% PAC at the same concentration 
only decreased C. histolyticum (173). In a recent interventional 
study, healthy volunteers had to ingest a dairy-based cocoa bever-
age with high (494 mg) or low (29 mg) flavanol content once a day 
for 4 weeks (174). The high flavanol beverage was composed of 
110 mg monomers (catechin and epicatechin), 99 mg dimers, and 
285 mg polymers (trimers to decamers), while the low flavanol 
beverage only contained 6, 11, and 12 mg of these compounds, 
respectively. The high flavanol drink significantly increased the 
counts of Bididobacterium, Lactobacillus, and Enterococcus and 
decreased those of C. histolyticum, while the low flavanol drink 
increased C. histolyticum. Both beverages stimulated the growth 
of the E. rectale/C. coccoides group. Accordingly, cocoa flavanols 
display a prebiotic potential by promoting a healthy IM in 
humans. In another human study, the effect of 2-week adminis-
tration of 0.19 g/day of a PAC-rich grape seed extract (DP 2–15) 
was evaluated on the IM composition and fecal odor in healthy 
adults (175). An increase of Bifidobacterium and a non-significant 
decrease of Enterobacteriaceae were reported. Interestingly, the 
concentrations of potentially harmful bacterial metabolites such 
as ammonia, phenol, p-cresol, 4-ethylphenol, indol, and skatol 
(eventually implicated in the development of colorectal cancer) 
tended to decrease. Methyl mercaptan gas concentrations and 
fecal odor decreased significantly. Therefore, in this study, the 
modification of the IM by PACs was associated with a healthier 
environment in the colonic ecosystem.
The study of PAC effects on the IM is not restricted to humans. 
In ruminant nutrition, PACs are recognized to modulate fermen-
tation processes in the rumen, inhibiting methane-producing 
archaea, decreasing bloating and protein degradation, and favor-
ing the formation of conjugated linoleic acid. Some studies suggest 
that body weight gain, milk yields, and reproductive performance 
could be also improved by incorporating tannins in the animal 
diet, even if there is not yet a clear explanation for these beneficial 
effects (155).
Transformation of PACs by Gut Microbiota
The enzymatic degradation of flavonoids by the colonic microbiota 
results in a huge array of new metabolites. Bacterial enzymes may 
catalyze many reactions including hydrolysis, dehydroxylation, 
demethylation, decarboxylation, and deconjugation (176). Many 
flavonoids undergo ring-fission in which their C-ring is degraded, 
A-ring forms hydroxylated aromatic compounds, and B-ring 
phenolic acids derivatives (177). Clostridium and Eubacterium 
have been proposed as the main bacterial genera involved in 
the metabolism of phenolic compounds including flavan-3-ols 
(178). It is considered that about 40% of the flavan-3-ols ingested 
with green tea are converted to phenolic acid metabolites in the 
colon, which are excreted in urine. About 8% of them are methyl, 
glucuronide, and sulfate derivatives of flavanols, which reflect 
the fact that these metabolites were previously absorbed by the 
colonic epithelium (179).
The first study carried out in humans by Das in 1971 identi-
fied 11 metabolites in urine after (+)-catechin intake; among the 
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most important were m-hydroxyphenylpropionic acid, δ-(3,4-
dihydroxyphenyl)-γ-valerolactone, and δ-(3-hydroxyphenyl)-
γ-valerolactone (180). These results were confirmed more 
recently by Li et al. who described phenyl-valerolactones as the 
main tea catechin metabolites produced by gut microorganisms 
and detected in human urine and blood (181). Consistently, 
Tzounis et  al. reported that the incubation of (−)-epicatechin 
or (+)-catechin with fecal bacteria led to the generation of 
5-(3′,4′-dihydroxyphenyl)-gamma-valerolactone, 5-phenyl-
gamma-valerolactone, and phenylpropionic acid (172). 
Valerolactones were also detected in human urine by Ottaviani 
et  al. after the consumption of flavanols and PCs (182). Aura 
et al. observed that 3-hydroxyphenyl propionic acid and 3-phe-
nylpropionic acid were the main metabolites originated from 
(+)-catechin and (−)-epicatechin by human microbiota (183). 
These results are consistent with those described by Gonthier 
et al. who also identified urinary and plasma 3-hydroxybenzoic 
acid and 3-hydroxyhippuric acid in rats fed a diet supplemented 
with red wine polyphenols (184). Flavanol degradation by the 
microbiota seems to be a rapid process completed in 4–8 h, as 
reported in a “pig cecum in vitro model” (185). In another study 
with pig microbiota, it was shown that about 80% of PC A2 and 
40% of cinnamtannin B1 were degraded after 8 h of incubation 
(186). 3-O-Gallate derivatives of epicatechin and epigallocatechin 
were extensively metabolized by a human fecal microbiota after 
24-h-incubation but remained unaffected in presence of rat fecal 
microbiota, even after 48-h-incubation. These results suggest 
differences in the microbiota and their associated metabolic abil-
ity between both species (187). Phenylvaleric, phenylpropionic, 
cinnamic, phenylacetic, and benzoic acids as well as conjugated 
derivatives of benzoic acid have been identified in urine samples 
of rats fed with PC dimer B3, trimer C2, and catechin polymer 
(74). In another study, the main metabolites identified after the 
in  vitro fermentation of purified PAC dimers with a human 
fecal microbiota were 2-(3,4-dihydroxyphenyl) acetic acid and 
5-(3,4-dihydroxyphenyl)-γ-valerolactone (167). m-hydroxyphe-
nylpropionic acid, ferulic acid, 3,4-dihydroxyphenylacetic acid, 
m-hydroxyphenylacetic acid, vanillic acid, and m-hydroxyben-
zoic acid were identified in urine samples of human volunteers 
after cocoa intake (188). These results were confirmed by Urpi-
Sarda et al. who reported increased urinary concentrations of caf-
feic acid, ferulic acid, 3-hydroxyphenylacetic acid, vanillic acid, 
3-hydroxybenzoic acid, 4-hydroxyhippuric acid, and hippuric 
acid in humans, while in rats were identified 3,4-dihydroxy-
phenylpropionic acid, m-coumaric acid, 3-hydroxyphenylacetic 
acid, protocatechuic acid and vanillic acid (189). These slight 
differences in the metabolite profile probably reflect interspecies 
differences in their microbiota composition. Ward et al. detected 
urinary 3-hydroxyphenylpropionic acid and 4-O-methylgallic 
acid after regular consumption of PAC-containing grape seed 
extract in humans (190). Interestingly, Jenner et  al. measured 
the concentrations of dietary polyphenols and their bacte-
rial metabolites in fecal waters from healthy omnivorous 
subjects under normal diet (i.e., without additional supple-
mentation  with fruits and vegetables). The major components 
detected were phenylacetic acid (479µM), 3- phenylpropionic 
acid (166µM), 3-(4-hydroxy)-phenylpropionic acid (68µM), 
3,4-dihydroxycinnamic acid (52µM), benzoic acid (51µM), 
3-hydroxyphenylacetic acid (46µM), and 4–hydroxypheny-
lacetic acid (19µM). Other phenolic acids ranged between 
0.04 and 7µM in fecal waters (19). The bacterial degradation of 
black tea polyphenol-rich and red wine/grape juice extracts by 
the colonic microbiota were compared in an in vitro five-stage 
GI model (SHIME®). The levels of gallic acid and 4-hydroxy-
phenylpropionic acid remained elevated throughout the colon 
with red wine/grape juice feeding, while these compounds were 
consumed in the distal colon and 3-phenylpropionic acid was 
strongly produced during a polyphenol-rich black tea extract 
feeding. The gut microbial production of phenolics was depend-
ent on their location in the colon and the extract source (191).
The PAC DP is an important factor affecting the microbial 
metabolism of these compounds. The presence of PACs with high 
DP prevents the in  vitro microbial metabolism of PACs (192), 
and A-type PACs are also more resistant to microbial degradation 
than B-type PACs (193). The main flavanol bacterial metabolites 
described in these studies are summarized in Table 6.
Whether these PAC metabolites can be used by the cells as a 
source of energy is unclear. A recent study showed that 3,4-dihy-
droxyphenylacetic acid, a microbial metabolite of quercetin and 
PACs, can protect against the mitochondrial dysfunction induced 
by CS in Min6 pancreatic β-cells (194). CS (320µM) decreased 
the mitochondrial membrane potential, the intracellular con-
centrations of ATP and the rate of oxygen consumption, while 
3,4-dihydroxyphenylacetic acid (100–250µM) prevented, in a 
concentration-dependent manner, these mitochondrial function 
alterations. At 250µM, this metabolite was capable of preventing 
the drop in oxygen consumption and complex I activity, suggest-
ing that 3,4-dihydroxyphenylacetic acid improves the energetic 
metabolism of these cells.
Protective effect of PACs in Colonic 
inflammation
Inflammatory bowel diseases, mainly Crohn’s disease and 
ulcerative colitis, are considered as a growing problem of public 
health in the world. The etiology of these diseases remains poorly 
understood. Although the mechanisms underlying the occur-
rence of Crohn’s disease and ulcerative colitis differ, both diseases 
are characterized by a chronic inflammation and increased 
oxidative stress in the mucosa, with an inappropriate activation 
of the immune system (195). Considering that dietary PACs 
exhibit antiinflammatory, immunomodulatory, and antioxidant 
properties, a number of studies have tested their impact in animal 
models of IBD (Table 7).
The oral administration of apple (mainly containing B1, B2, 
and C1 PACs) or grape seed extract (with 75% PACs: 40% poly-
mers, 14% dimers, 12% trimers, 8% tetramers) has been shown to 
prevent colonic damage in an experimental colitis model induced 
by dextran sodium sulfate or oxazolone in rodents (196–199). 
Accordingly, the mortality rate of the treated animals as well as 
their weight loss was lower, compared with those receiving the 
placebo. The grape extract also contributes to the normalization 
of the ileal villus morphology and mucosal thickness, reducing 
the histological severity score in the distal ileum and proximal 
colon (197). It has been postulated that one of the mechanisms 
TABle 6 | Flavanol metabolites identified from microbial conversion (in vitro) or in body fluids (in vivo).
Flavanols Metabolites Reference
(+)-catechin 3-hydroxyphenylpropionic acid Human urine and feces (180)
5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone
Human urine and blood (181)
3-hydroxyphenylpropionic acid
3-hydroxybenzoic acid
3-hydroxyhippuric acid
3,4-dihydroxyphenylpropionic acid
3,4-dihydroxyphenylacetic acid
Ferulic acid
Rat urine and plasma (184)
3,4-dihydroxyphenylpropionic acid (inoculum A)
3-hydroxyphenylpropionic acid (inoculum A)
3-phenylpropionic acid (inoculum A)
3,4-dihydroxyphenylvaleric acid (inoculum B)
3-hydroxyphenylvaleric acid (inoculum B)
Human fecal microbiota (183)
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone
5-phenyl-γ-valerolactone
Phenylpropionic acid
Human fecal microbiota (172)
3,4-dihydroxyphenylpropionic acid
4-hydroxyphenylacetic acid
4-hydroxybenzoic acid
Porcine fecal microbiota (185)
(−)-epicatechin 3-hydroxyphenylpropionic acid Human urine and feces (180)
3-hydroxyphenylpropionic acid (inoculum A)
3-phenylpropionic acid (inoculum A)
3,4-dihydroxyphenylvaleric acid (inoculum B)
3-hydroxyphenylvaleric acid (inoculum B)
Human fecal microbiota (177)
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone
5-phenyl-γ-valerolactone
Phenylpropionic acid
Human fecal microbiota (172)
3,4-dihydroxyphenylpropionic acid
4-hydroxyphenylacetic acid
4-hydroxybenzoic acid
Porcine fecal microbiota (185)
(−)-epigallocatechin and 
(−)-epigallocatechingallate
4-phenylacetic acid
3- and 4-hydroxybenzoic acid
Gallic acid
Porcine fecal microbiota (185)
Proanthocyanidins 3-hydroxyphenylpropionic acid
3,4-dihydroxyphenylacetic acid
3-hydroxyphenylvaleric acid
Phenylacetic acid
3-hydroxyphenylacetic acid
3,4-dihydroxyphenylacetic acid
3-hydroxybenzoic acid
4-hydroxybenzoic acid
Hippuric acid
Vanillic acid
Caffeic acid
Ferulic acid
3-Methoxy, 4-hydroxyphenilvalerolactone
3,4-dihydroxyphenylvalerolactone
Rat urine (74)
3-hydroxyphenylpropionic acid
Ferulic acid
3,4-dihydroxyphenylacetic acid
3-hydroxyphenylacetic acid
Vanillic acid
3-hydroxybenzoic acid
4-hydroxybenzoic acid
Human urine (188)
(Continued )
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Flavanols Metabolites Reference
Caffeic acid
Ferulic acid
3-hydroxyphenylacetic acid
Vanillic acid
3-hydroxybenzoic acid
4-hydroxyhippuric acid
3,4-dihydroxyphenylpropionic acid
Human and rat urine (189)
3-hydroxyphenylpropionic acid
4-O-methylgallyc acid
Human urine (190)
2-(4-hydroxyphenyl)acetic acid
2-(3-hydroxyphenyl)acetic acid
3-(4-hydroxyphenyl)propionic acid
3-hydroxyphenylpropionic acid
5-(3-hydroxyphenyl)valeric acid
3-phenylpropionic acid
Human fecal microbiota (18)
2-(3,4-dihydroxyphenyl)acetic acid
5-(3,4-dihydroxyphenyl)-γ-valerolactone
Human fecal microbiota (167)
3-(4-hydroxyphenyl)propionic acid
3-hydroxyphenylpropionic acid
3,4-dihydroxyphenylacetic acid
4-hydroxyphenylacetic acid
Porcine fecal microbiota (186)
TABle 6 | Continued
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implicated in these effects should be the modulation of the pro-
portions of the TCRγδ/TCRαβ intraepithelial lymphocytes. Indeed, 
these cells play a key role in the maintenance of mucosal homeo-
stasis, contributing to the modulation of the activated release of 
pro-inflammatory cytokines by epithelial cells and, therefore to 
the prevention of inflammatory states in the mucosa (196, 200).
Grape seed extract (containing PACs >95%, dimeric >1.8%, 
oligomers >60%) also exerted a protective effect in recurrent coli-
tis induced by the intracolonic injections of 2,4,6-trinitrobenzene 
sulfonic acid, reducing the colonic weight/length ratio and the 
microscopic and macroscopic damage scores (201–204). Such 
effect relied on the antiinflammatory and antioxidant properties 
of the extract, as it was shown to inhibit the NF-κB signaling path-
way, reducing the expression levels of TNF-α, p-IKKα/β, p-IκBα, 
and the translocation of NF-κB to the nucleus of colonic epithelial 
cells (203, 204). As a consequence of these events, the animal 
treated with the extract exhibited a lower neutrophil infiltration 
in their colonic mucosa, a decrease of IL-1β concentration, lipid 
peroxidation, and colonic inducible nitric oxide synthase activ-
ity, while the concentrations of IL-2 and IL-4, the antioxidants 
enzymes activities, and the levels of glutathione increased. These 
effects were comparable to those obtained with sulfasalazine, the 
standard drug used for IBD treatment (201–204).
The antiinflammatory properties of polymeric PACs from 
Pistacia vera L. nuts and apple has been studied in cell models 
(Caco-2 and T84 cell lines) simulating some conditions of IBD 
through their activation by pro-inflammatory cytokines such 
as IL-1β or IFN-γ/IL-1β/TNF-α (205, 206). Apple and pistachio 
PACs was shown to prevent the cytokine-induced translocation 
of NF-κB to the nucleus and the subsequent secretion of pro-
inflammatory cytokines by these epithelial cells. More specifically, 
B1 PAC inhibited in a dose-dependent manner the expression 
of pro-inflammatory genes and repressed NF-κB-, IP-10-, and 
IL-8-promoters and STAT1-dependent signal transduction (206). 
The PAC extract from pistachio also contributes to conserve the 
integrity of IL-1β-stimulated Caco-2 cell monolayers by attenu-
ating the disruption of tight-junctions, preventing the drop in 
transepithelial electrical resistance and the alterations of the gut 
barrier function (205).
In a recent in vitro study, we investigated the protective effect 
of PAC-containing polyphenol extracts from apple, avocado, 
cranberry, or grape and PACs microbial metabolites on the del-
eterious effect induced by p-cresol in human colonic epithelial 
cells (HT-29 and Caco-2). In HT-29 cells, the cranberry and 
avocado extracts prevented the loss in cell viability (measured 
as lactate dehydrogenase leakage) and the diminution in ATP 
contents, while bacterial metabolites only prevented the loss in 
cell viability. In Caco-2 cells, all extracts and bacterial metabolites 
prevented the p-cresol-induced alterations of barrier function 
(measured as transepithelial electrical resistance and fluorescein-
dextran transport). These results suggest that PAC-containing 
polyphenol extracts and PAC metabolites likely contribute to the 
protection of the colonic mucosa against the deleterious effects 
of p-cresol (207).
Protective effect of PACs on Colorectal 
Cancer
Colorectal cancer is strongly related to dietary habits and is one 
of the most common cancers worldwide (208). Many studies have 
assessed the impact of flavonoids including PACs on the risk of 
this cancer (11, 209–212). In vitro studies using human cells lines 
derived from colonic adenocarcinoma have reported an inhibi-
tory effect of PACs on cell proliferation and growth (213–215), 
an increase of apoptosis associated to caspase 3 (213, 215, 216) 
TABle 7 | Protective effect of proanthocyanidins in animal models of colonic inflammation.
extract extract administration experimentally induced colitis effect Reference
Apple 
PACs
0.1, 0.3, or 1% in drinking water 
ad libitum for 14 days before DSS 
treatment
DSS in drinking water ad libitum ↓ colonic damage
↓ mortality rate
↓ body weight loss
↑ TCRγδ and TCRαβ T cells in IEL
(196)
1% in drinking water ad libitum 
for 7 days before oxazolone 
administration
7.5 mg/ml oxazolone i.r. ↓ body weight loss (196)
0.005–0.0025% with PMA PMA-induced inflammation in colon 
epithelial cell line Caco-2 PMA  
300 ng/ml for 6 h
↓ secretion of IL-8 (196)
Grape 
seed 
PACs
400 mg/kg/day for 10 days DSS in drinking water ad libitum
From days 5–10
↓ ileal villus height
↓ mucosal thickness
↓ histological severity score in the distal ileum and 
in proximal colon
(197)
PACs-rich 
grape 
seed 
extract
100, 200, and 400 mg/kg/day for 
7 days after first TNBS injection
Twice i.r. injection
First 100 mg/kg TNBS, after 4 days 
75 mg/kg
↓ colonic weight/length
↓ body weight loss
↓ microscopic and macroscopic damage score
↓ MPO activity
↓ lipid perocidation
↓ IL-1β levels
↑ IL-2 and IL-4 levels
(201)
100, 200, and 400 mg/kg/day for 
7 days after first TNBS injection
Twice i.r. injection
First 80 mg/kg TNBS, after 16 days 
30 mg/kg
↓ body weight loss
↓ microscopic and macroscopic damage score
↑ SOD and GSHpx activity
↑ GSH levels
↓ expression of TNF-α, p-IKKα/β, p-IκBα
↓ translocation NF-κB
(204)
100, 200, and 400 mg/kg/day for 
7 days after second TNBS injection
(203)
200 mg/kg/day for 7 days after 
second TNBS injection
Twice i.r. injection
First 80 mg/kg TNBS, after 16 days 
30 mg/kg
↓ colonic weight/length
↓ body weight loss
↓ microscopic and macroscopic damage score
↓ MPO and iNOS activity
↓ lipid perocidation
↓ Nitric oxide levels
↑ SOD and GSHpx activity
↑ GSH levels
(202)
DSS, dextran sulfate sodium; IEL, intraepithelial lymphocytes; iNOS, inducible nitric oxide synthase; GSH, glutathione; GSHpx, glutathione peroxidase; IL, interleukin; i.r. intrarectally; 
PMA, phorbol 12-myristate 13-acetate; SOD, superoxide dismutase; TNBS, 2,4,6-trinitrobenzene sulfonic acid; TNF-α, tumor necrosis factor alpha.
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or caspase 8 activation (217), an arrest of the cell cycle in G1 
phase (215), or the suppression of the angiogenic factors vascular 
endothelial growth factor and angiopoietin 1 (in a model of 
tumor growth in a xenografted chick chorio-allantoic membrane) 
(218). In animals, grape seed PACs (0.1–1.0% of diet) inhibited 
by 72–88% the formation of aberrant colonic crypt foci induced 
by azoxymethane and by 20–56% the activity of ornithine decar-
boxylase, an enzyme involved in cell growth and differentiation 
and related to tumor promotion, in the distal colon (219). In 
another study using the same model, the administration PACs 
(0.002%) and PC B2 (0.05%) decreased aberrant crypt foci forma-
tion and cell proliferation in the colonic epithelium and increased 
apoptosis compared with control rats (220).
In humans, a case–control study carried out in Italy reveals 
a decreased risk of colorectal cancer in the subjects with higher 
intakes of PACs [odds ratio (OR)  =  0.74], being this effect 
more effective for rectal than for colon cancer (221). Another 
case–control study in Scotland showed a reduction in the risk of 
colorectal cancer with the consumption of catechin (OR = 0.68 
for the highest vs lowest quartile), epicatechin (OR = 0.74), and 
PCs (OR = 0.78) (222), while a study in Spain showed a decreased 
risk in the quartile of highest intake of PAC compared with that 
of lowest intake [OR = 0.58 CI95% (0.35–0.96), p = 0.02]. In this 
study, PACs were mainly brought by fruits, wine, and legumes 
and similar to the Italian study, the protective effect of PACs was 
more pronounced for rectal than for colon cancer (223). In oppo-
sition with these studies, another Scottish case–control study and 
the prospective Iowa Women’s Health Study did not detect any 
association between PAC intake and colorectal cancer (224, 225) 
and Bobe et  al., in 1,859 participants of the Polyp Prevention 
Trial, reported an association between PAC intake and the risk of 
colorectal adenoma recurrence in men (226).
In conclusion, although in  vitro, in  vivo, and epidemiologic 
studies suggest that PACs could act as a chemopreventive agent, 
further studies are necessary to confirm these results and to clearly 
establish the subjacent mechanisms implicated and the type and 
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CONCluSiON
During the postprandial period, high amounts of undigested 
dietary PACs are found in the gut lumen where they exert great 
number of activities beneficial for the health host. They contribute 
to the host defense against pathogens, the modulation of gastric 
emptying, the inhibition of emetic reflex, and the modulation 
of the composition of the IM in the colon, in a prebiotic-like 
manner. They also decrease the inflammatory and pro-oxidant 
processes occurring in the gastric and colonic mucosa, favoring 
ulcer healing and contributing to the GI mucosa integrity. In the 
small intestine, they interfere with the digestion and absorption 
of carbohydrates, proteins, lipids, and eventually LPS, and can 
modulate the secretion of GI hormones, the epithelial transport 
of water and electrolytes, and the GI transit. In the colon, PAC 
could act reducing the risk of colorectal cancer. Their degradation 
by the gut microbiota generates several metabolites with protec-
tive properties for the colonic epithelium and, when absorbed, for 
the extra-intestinal tissues. The numerous properties of PACs in 
the GI tract probably represent a large part of their overall effects 
on human health and contribute to explain the impact of the con-
sumption of fruits and vegetables against the non-communicable 
chronic diseases. Due to these properties, they could eventually 
be used for the dietary management of several GI diseases, or 
as complementary treatment to attenuate adverse effects associ-
ated with the administration of certain drugs. However, further 
investigations are necessary to fully understand the mechanisms 
and effects of their use, as well as the doses and formulations nec-
essary to generate the desired effects. Finally, since the beneficial 
effects of PACs are not only limited to humans, as shown by 
their positive effects in ruminant nutrition; accordingly, PACs 
could also be used to improve the productivity in livestock 
 breeding and the healthy properties of animals products.
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